valu usd unless otherwis note
confid revenu growth acceler
 need out-performance
view rais ep guidanc howev question remain
regard slope recoveri medic deliveri clinic
peer ytd believ confid acceler organ
revenu growth need drive continu out-performance
result larg line exclud non-oper item
milestone/r time sale highlight quarter
perform beat consensu
pharmaceut strength driven clari new product launch
dexmedetomidin hydrochlorid market opportun
eptifibatid ou pharmaci compound servic anesthesia
separ deliv adjust dilut ep exceed
guidanc ep beat due lower tax rate
fce drove nickel beat lower
ratio also benefit shift mileston
payments/r spend
slope recoveri medic deliveri clinic nutrit
busi remain key question investor mind comp
lvp easier remaind particularli destock
 lvp began june separ benefit
recent west pharma recal work recaptur
share mini-bag mini-bag product infus pump
launch spectrum iq north america evo iq
uk ireland australia final compani recent expand
lipid portfolio clinolipid howev manag believ
recoveri clinic nutrit take longer given practic chang
stori
updat estim rais price target maintain
revenu estim y/i constant currenc
ep estim increas y/i owe
lower tax rate separ revenu estim remain
larg unchang y/i constant currenc
estim remain unchang y/i rais price
target impli ebitda
organ upsid manag ep guid appear difficult
achiev recal manag expect adjust
dilut ep fce continu believ upsid
manag target seem difficult absent aggress
capit deploy manag deploy cash buy
back share last two quarter serv off-set
medic deliveri clinic nutrit reset higher stock
option exercis howev estim still share
buyback/m firepow use augment organ growth
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
rate share sector perform
currenc revenu growth sale grow
compound annual basi
grew previou hospit product busi y/i
organ constant currenc basi ex cyclo
compound-annual-growth-rate exclud acquisitions/divestitur
addit note patient growth end-stag
renal diseas esrd mid-singl digit y/i final note
analysi larg cap md peer also point mid-
single-digit y/i averag top-line growth bax peer group
potenti upsid could come futur
bax long-term oper margin target
appear achiev manag expect
adjust oper margin
perform analysi look averag oper
margin bax hospit product renal peer
weight hospit product renal peer averag base
expect sale mix would point
potenti oper margin low-to-mid
line manag current guidanc
addit upsid could come layer deal
higher-than-averag corpor margin
balanc sheet/m would sourc upsid
manag expect grow revenu
driven oper growth
new product bake figur
believ manag use capit tuck-in
faster-grow market improv bax margin
bloomberg capit market estim upside/downside/target
base case current assum grow top-line
compound-annual-growth-rate assum adjust oper
margin expand line manag
updat long-rang plan impli grow cash
ep low-doubl digit low teen
large-cap med-tech peer group price target
impli adjust ebitda estim support
sector perform rate
upsid scenario assum acceler
sustain top-line growth assum
adjust oper margin expand
manag long-rang plan driven partli
acret impli grow cash ep
low-to-mid-teen well large-cap
med-tech peer group scenario believ share
could trade high next month
downsid scenario current assum grow
top-line compound-annual-growth-rate consensu
expect structur growth
medic
deliveri clinic nutrit persist assum
manag fall short adjust oper margin target
reinvest grow top line
assum grow cash ep high-singl digit
line large-cap med-tech peer group
scenario believ share could trade low
next month
perform discount cash flow dcf price-to-earnings ev/ebitda analysi come
intrins valu share get price target assign weight
intrins valu calcul dcf analysi weight
intrins valu calcul price-to-earnings analysi weight
intrins valu calcul ev/ebitda analysi assumpt use
analysi includ follow dcf analysi use wacc assum termin
valu ev/ebitda multipl separ assign target forward price-to-earnings multipl
slightli bax large-cap peer group averag target forward
ev/ebitda multipl slightli large-cap peer group averag
believ slight discount group averag multipl warrant given recent top-line
growth concern price target support sector perform rate
risk rate price target
baxter face risk typic global diversifi healthcar compani risk
includ competit currenc patent litig reimburs clinic trial risk
navig fda
oper two segment hospit product renal medic
product busi sell intraven iv solut administr set premix drug
drug-reconstitut system pre-fil vial syring inject drug iv nutrit
product infus pump inhal anesthet busi also provid product
servic relat pharmaci compound drug formul packag technolog
renal busi provid product servic treat end-stag renal diseas
irrevers kidney failur along renal therapi busi enhanc
acquisit gambro ab gambro bax renal busi offer
comprehens portfolio meet need patient across treatment continuum
includ technolog therapi periton dialysi pd in-cent hemodialysi
hd home hd hhd continu renal replac therapi crrt addit dialysi
servic baxter spun previou bioscienc busi juli busi
acquir shire januari
net incom attribut baxter
